Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.62 |
| ▸ | HTR2B | P41595 | 8/20 | 0.53 |
| ▸ | HTR2A | P28223 | 6/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622196 | 0.86 | HTR2C (0.60) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1621919 | 0.79 | HTR2C (0.61) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1620484 | 0.77 | HTR2C (1.00) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1622353 | 0.74 | HTR2C (0.74) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1622358 | 0.71 | HTR2C (0.79) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1622749 | 0.71 | HTR2C (0.73) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1622904 | 0.69 | HTR2C (1.00) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1620840 | 0.68 | HTR2C (0.73) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL1623063 | 0.68 | HTR2C (0.72) | HTR2CHTR2BHTR2AHTR1ADRD2 | |
| SCHEMBL12719518 | 0.68 | HTR2C (0.70) | HTR2CHTR2BHTR2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| EP-2139896-A1 | PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | Pfizer Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.